Your browser doesn't support javascript.
loading
Radiolabeling of Theranostic Nanosystems.
Das, Sudeep; Imlimthan, Surachet; Airaksinen, Anu J; Sarparanta, Mirkka.
Afiliación
  • Das S; Department of Chemistry, University of Helsinki, Helsinki, Finland.
  • Imlimthan S; Department of Chemistry, University of Helsinki, Helsinki, Finland.
  • Airaksinen AJ; Department of Chemistry, University of Helsinki, Helsinki, Finland.
  • Sarparanta M; Turku PET Centre, Department of Chemistry, University of Turku, Turku, Finland.
Adv Exp Med Biol ; 1295: 49-76, 2021.
Article en En | MEDLINE | ID: mdl-33543455
ABSTRACT
In the recent years, progress in nanotechnology has significantly contributed to the development of novel pharmaceutical formulations to overcome the drawbacks of conventional treatments and improve the therapeutic outcome in many diseases, especially cancer. Nanoparticle vectors have demonstrated the potential to concomitantly deliver diagnostic and therapeutic payloads to diseased tissue. Due to their special physical and chemical properties, the characteristics and function of nanoparticles are tunable based on biological molecular targets and specific desired features (e.g., surface chemistry and diagnostic radioisotope labeling). Within the past decade, several theranostic nanoparticles have been developed as a multifunctional nanosystems which combine the diagnostic and therapeutic functionalities into a single drug delivery platform. Theranostic nanosystems can provide useful information on a real-time systemic distribution of the developed nanosystem and simultaneously transport the therapeutic payload. In general, the diagnostic functionality of theranostic nanoparticles can be achieved through labeling gamma-emitted radioactive isotopes on the surface of nanoparticles which facilitates noninvasive detection using nuclear molecular imaging techniques, such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), meanwhile, the therapeutic effect arises from the potent drug released from the nanoparticle. Moreover, some radioisotopes can concurrently emit both gamma radiation and high-energy particles (e.g., alpha, beta, and Auger electrons), prompting the use either alone for radiotheranostics or synergistically with chemotherapy. This chapter provides an overview of the fundamentals of radiochemistry and relevant radiolabeling strategies for theranostic nanosystem development as well as the methods for the preclinical evaluation of radiolabeled nanoparticles. Furthermore, preclinical case studies of recently developed theranostic nanosystems will be highlighted.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Nanopartículas / Medicina de Precisión Tipo de estudio: Prognostic_studies Idioma: En Revista: Adv Exp Med Biol Año: 2021 Tipo del documento: Article País de afiliación: Finlandia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Nanopartículas / Medicina de Precisión Tipo de estudio: Prognostic_studies Idioma: En Revista: Adv Exp Med Biol Año: 2021 Tipo del documento: Article País de afiliación: Finlandia